secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0001493152-24-030102
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M
----------------------------------------------------------------------

- Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.
- Operating income $2.2M vs $0.8M in prior-year quarter; income from continuing ops $2.1M vs $0.4M.
- Adjusted EBITDA $2.3M vs $1.3M; cash collections $11.0M (+7% YoY).
- Cash balance $2.0M at June 30, 2024, down from $5.1M due to $4.6M additional long-term debt paydown.
- Gross profit margin stable at 62%; operating expenses down ~14% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224030102/0001493152-24-030102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224030102/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer